Mabthera: Clinical Trials

17 trials of Mabthera, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

10 completed, 3 terminated, 2 unknown, 1 not yet recruiting. 17 Phase 4.

By phase and status

PhaseTrialsStatus
Phase 417Completed 10, Terminated 3, Unknown 2, Not yet recruiting 1, Recruiting 1

Follow Mabthera: new trials by email Literature Review of Mabthera trials Research Report on Mabthera

Trials (filtered) newest first · largest first

All 17 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Comparison of a Strategy Based on Clinico-biological Monitoring Versus Pre-emptive Rituximab Treatment in Cases of ANCA Reappearance in Granulomatosis With Polyangiitis and Microscopic Polyangiitis.
Rituximab - ANCA Associated Vasculitis (AAV), Polyangiitis (GPA)
Phase 4Not yet recruitingAssistance Publique - Hôpitaux de Paris702026-02-012026-03-05
Tapering of Rituximab Based on Interval Prolongation Compared to Disease Activity-guided Dose Reduction in Patients With Rheumatoid Arthritis
Rituximab - Rheumatoid Arthritis
Phase 4RecruitingUniversitaire Ziekenhuizen KU Leuven1342024-01-092025-05-31
IVIG/Rituximab vs Rituximab in Kidney Transplant With de Novo Donor-specific Antibodies
Rituximab, intravenous immune globulin - Renal Transplant
Phase 4CompletedSeoul National University Hospital502019-01-082022-10-26
The Comparison of RCD Versus BCD in Newly Diagnosed Waldenström Macroglobulinemia
Bortezomib, Rituximab - Waldenström Macroglobulinemia
Phase 4CompletedInstitute of Hematology & Blood Diseases Hospital, China352016-05-012026-02-11
A Randomized, Multi-Center Biomarker Trial to Predict Therapeutic Responses of Patients With Rheumatoid Arthritis to a Specific Biologic Mode of Action
Remicade, Orencia, Ro-Actemra - Rheumatoid Arthritis
Phase 4CompletedMedical University of Vienna1152012-05-012018-10-31
Rituximab in Recurrent IgA Nephropathy
Intravenous Rituximab, ACEI/ARB and corticosteroids - Recurrent IgA Nephropathy
Phase 4UnknownChulalongkorn University302012-01-012015-10-08
Rituximab (RTX) Therapy in Patients With Active TAO
Rituximab, Iv Methylprednisolone, peroral methylprednisolone and Methotrexate - Ophthalmopathy, Thyroid-Associated
Phase 4CompletedGöteborg University382011-12-012025-03-26
A Study of Rituximab in Combination With Fludarabine and Cyclophosphamide in Participants With Chronic Lymphocytic Leukemia and Favorable Somatic Status
Cyclophosphamide, Fludarabine, Rituximab - Lymphocytic Leukemia, Chronic
Phase 4TerminatedHoffmann-La Roche892011-06-172018-03-20
A Study to Compare Mabthera (Rituximab), Fludarabine and Cyclophosphamide to Mabthera and Chlorambucil in Participants With Chronic Lymphocytic Leukemia and Unfavorable Somatic Status
Chlorambucil, Cyclophosphamide, Fludarabine - Lymphocytic Leukemia, Chronic
Phase 4TerminatedHoffmann-La Roche262011-04-272019-03-14
De Novo Everolimus-based Therapy for Renal Transplantation Using Rituximab Induction
rituximab and everolimus, thymoglobulin and tacrolimus - Renal Insufficiency
Phase 4TerminatedNational Taiwan University Hospital22011-04-012012-12-27
RituxiMab INDuction in Renal Transplantation
Rituximab, Tacrolimus, Mycophenylate mofetil - Function of Renal Transplant
Phase 4UnknownGuy's and St Thomas' NHS Foundation Trust1002010-11-012020-07-22
Low Dose Rituximab as a First Line Biologic Therapy for the Treatment of DMARD Resistant Patients With Rheumatoid Arthritis
Rituximab - DMARD Resistant Rheumatoid Arthritis
Phase 4CompletedMashhad University of Medical Sciences442010-07-012012-05-08
Optimal Management of Rheumatoid Arthritis Patients Requiring Biologic Therapy
etanercept or adalimumab, Rituximab - Rheumatoid Arthritis
Phase 4CompletedUniversity of Glasgow3022010-04-012015-05-29
The Study of Different Dose Rituximab in the Treatment of ITP
Rituximab - Purpura, Thrombocytopenic, Idiopathic, Immune Thrombocytopenia
Phase 4CompletedShandong University622010-01-012017-08-23
A Study of MabThera (Rituximab) in Combination With Methotrexate in Patients With Rheumatoid Arthritis Who Have Had an Inadequate Response to Anti-TNF Therapies.
rituximab, Methotrexate, Corticosteroid or NSAID - Rheumatoid Arthritis
Phase 4CompletedHoffmann-La Roche402007-06-012014-11-04
Study of Rituximab to Treat Chronic Renal Transplant Rejection
Rituximab, Control arm - Kidney Transplantation, Graft Rejection
Phase 4CompletedKing's College London622007-01-012020-03-05
Efficacy Response Duration and Toxicity of Rituximab, Fludarabine, and Cyclophosphamide (RFC) as 1st Line Treatment and Rituximab (R) in Maintenance Treatment in Follicular Non Hodgkin (FNH) Lymphoma
Rituximab Fludarabine Cyclophosphamide - Non Hodgkin Lymphoma
Phase 4CompletedAsociacion Espanola de Hematologia y Hemoterapia752004-09-012010-05-17

Conditions studied

Arthritis, Rheumatoid (5)  ·  Leukemia, Lymphocytic, Chronic, B-Cell (2)  ·  Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (1)  ·  Glomerulonephritis, IGA (1)  ·  Granulomatosis with Polyangiitis (1)  ·  Graves Ophthalmopathy (1)  ·  Lymphoma, Non-Hodgkin (1)  ·  Microscopic Polyangiitis (1)  ·  Purpura (1)  ·  Purpura, Thrombocytopenic, Idiopathic (1)  ·  Renal Insufficiency (1)  ·  Systemic Vasculitis (1)  ·  Thrombocytopenia (1)  ·  Waldenstrom Macroglobulinemia (1)

Sponsors

Hoffmann-La Roche (3)  ·  Asociacion Espanola de Hematologia y Hemoterapia (1)  ·  Assistance Publique - Hôpitaux de Paris (1)  ·  Chulalongkorn University (1)  ·  Guy's and St Thomas' NHS Foundation Trust (1)  ·  Göteborg University (1)  ·  Institute of Hematology & Blood Diseases Hospital, China (1)  ·  King's College London (1)  ·  Mashhad University of Medical Sciences (1)  ·  Medical University of Vienna (1)  ·  National Taiwan University Hospital (1)  ·  Seoul National University Hospital (1)  ·  Shandong University (1)  ·  Universitaire Ziekenhuizen KU Leuven (1)  ·  University of Glasgow (1)

Countries

Russia (3)  ·  United Kingdom (3)  ·  China (2)  ·  South Korea (2)  ·  Austria (1)  ·  Belgium (1)  ·  Czechia (1)  ·  France (1)  ·  Iran (1)  ·  Spain (1)  ·  Sweden (1)  ·  Switzerland (1)  ·  Taiwan (1)  ·  Thailand (1)

Top investigators

A. Paz Coll, MD (1)  ·  A. Salar, MD (1)  ·  Anthony Dorling, PhD FRCP (1)  ·  C. Cabrera Silva, MD (1)  ·  Daniel Aletaha, MD (1)  ·  Duncan Porter, BM BCh (1)  ·  E . Prieto Pareja, MD (1)  ·  Helena Filipsson, Ass Prof (1)

Results publications

PMID 20546023, PMID 21674758, PMID 21710166, PMID 23293082, PMID 27040278, PMID 27197690, PMID 27889300, PMID 32117242, PMID 34792562, PMID 35049070, PMID 37169835, PMID 38205507, PMID 39407334, PMID 8217798

NIH funding

2009 (2), 2025 (1)